No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ENTX Entera Bio
- 1.7600
- -0.0500-2.76%
Trading Jul 22 10:55 ET
63.42MMarket Cap-6285P/E (TTM)
1.8400High1.7350Low16.35KVolume1.8400Open1.8100Pre Close28.76KTurnover0.07%Turnover RatioLossP/E (Static)36.03MShares3.350052wk High7.15P/B43.80MFloat Cap0.520052wk Low--Dividend TTM24.89MShs Float10.1600Historical High--Div YieldTTM5.80%Amplitude0.4722Historical Low1.7580Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Ram Selvaraju maintains $Entera Bio(ENTX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 36.8% and a
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients With Hypoparathyroidism at ENDO 2024
JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced Phase 1
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, toda
Express News | HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Entera Bio to Present Phase 1 Data From First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it
Entera Bio Releases Crucial Financial Information Update
Comments
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
$Entera Bio(ENTX.US$ Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
$Entera Bio(ENTX.US$ Entera Bio Receives Extension From Nasdaq to Regain Compliance With Minimum Bid Price Rule![]()
1
$Entera Bio(ENTX.US$ Lets do the house keeping first! Have until 12/26/23 For trade over dollar 30 days to regain compliance! NOT a chance. So R/S may happen? But they could also get 1 more 180 day extension? Waiting to see?
Now to the WATCHING REMINDER! And i will just give you the company’s words for this! PAY ATTENTION TO LAST SENTENCE ! (((((( EB612: First Oral PTH(1-34) Peptide Replacement Therapy Tablets for Hypoparathyroidism
EB612, is the first oral formu...
Now to the WATCHING REMINDER! And i will just give you the company’s words for this! PAY ATTENTION TO LAST SENTENCE ! (((((( EB612: First Oral PTH(1-34) Peptide Replacement Therapy Tablets for Hypoparathyroidism
EB612, is the first oral formu...
2
$Entera Bio(ENTX.US$
EB613: First Oral PTH(1-34) Daily Osteoanabolic Tablets for Osteoporosis
EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis. Entera is prepared to initiate a pivotal phase 3 study in post-menopausal women with high-risk osteoporosis and no prior fracture. Entera successfully completed a phase 2, 6-month, 161-patient, placebo-con...
EB613: First Oral PTH(1-34) Daily Osteoanabolic Tablets for Osteoporosis
EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis. Entera is prepared to initiate a pivotal phase 3 study in post-menopausal women with high-risk osteoporosis and no prior fracture. Entera successfully completed a phase 2, 6-month, 161-patient, placebo-con...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : Excuse me, can shares held still be valid after ENDPQ's restructuring?